Immunology

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

The FDA has lifted the clinical hold on CytoDyn’s leronlimab, allowing the company to evaluate the therapy as a treatment…

Can artificial intelligence automate lupus nephritis diagnoses?

Systemic lupus erythematosus (SLE) is a systemic, inflammatory, chronic autoimmune disease that can affect multiple organs simultaneously or sequentially, with…

Could microRNAs offer a new approach to lupus nephritis diagnosis?

Over the recent years, research into systemic lupus erythematosus (SLE) has focused on understanding the needs of patients with lupus…

Travere signs $120m licencing deal with Renalys for sparsentan in Asia

Travere Therapeutics has signed a licencing agreement for sparsentan with Japan-based Renalys Pharma for multiple Asian countries. As per the…

Evommune begins Phase I trial of EVO756 for spontaneous urticaria

Evommune has commenced a Phase I first-in-human clinical trial of new oral treatment, EVO756, for chronic spontaneous urticaria (CSU). The…

Roche and Novartis’ Xolair set for FDA priority review in food allergies

Genentech (Roche) and Novartis’ Xolair (omalizumab) could soon become a treatment option for multiple food allergy reactions after the FDA…

The opportunities arising from the unmet needs in bronchiectasis

With the increasing prevalence rate of bronchiectasis over the years, patients, physicians, and pharmaceutical companies are seeking effective management and…

FDA fast tracks Alladapt’s multi-food allergy immunotherapy

The US Food and Drug Administration (FDA) has granted a fast track designation to Alladapt Immunotherapeutics’ IgE-mediated multi-food oral immunotherapy…

Immix to assess cell therapy in Phase Ib/IIa AL amyloidosis trial

Immix Biopharma is set to assess its investigational chimeric antigen receptor T (CAR-T) cell therapy, BCMA CAR-T NXC-201 (previously HBI0101),…

Pharming doses first paediatric patient in APDS therapy trial

Pharming Group has dosed the first patient in a Phase III clinical trial assessing its investigational drug leniolisib’s new paediatric…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close